Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-2 Glucoregulatory Effects
NCT04043065Phase 1Completed
- Sponsor
- Gentofte Hospital
- Start
- Jan 2019
- Primary completion
- May 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of liver-expressed antimicrobial peptide 2 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Gentofte Hospital. Primary endpoints: Plasma insulin levels and Beta-cell secretion assessed by plasma C-peptide. Started Jan 2019; status: completed.
02
Drugs
liver-expressed antimicrobial peptide 2
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04043065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04043065.